VEGFA and neoplasm: Combination treatment of B20.4-1.1, a monoclonal VEGF neutralizing antibody, and PEG- hyaluronidase significantly improved tumor tissue perfusion with Hoechst 33342, a surrogate marker for delivery of cytostatic therapy compared to B20 alone.